The Electrocardiographic Manifestations of Arrhythmogenic Right Ventricular Dysplasia

Li Zhang1, Liwen Liu2, Peter R. Kowey1 and Guy H. Fontaine3

1Lankenau Medical Center, Lankenau Institute for Medical Research, Jefferson Medical College, Philadelphia, Pennsylvania, USA; 2Xijing Hospital, Forth Military Medical University, Xi’an, Shaanxi, China; 3Hôpital de la Salpêtrière, Paris, France

Abstract: The ECG is abnormal in most patients with arrhythmogenic right ventricular dysplasia (ARVD). Right ventricular parietal block, reduced QRS amplitude, epsilon wave, T wave inversion in V1-3 and ventricular tachycardia in the morphology of left bundle branch block are the characteristic changes that reflect the underlying genetic predetermined pathology and pathoelectrophysiology. Recognizing the characteristic ECG changes in ARVD will be of help in making a correct diagnosis of this rare disease.

Keywords: ECG, ARVD, desmosomal genes, ventricular tachyarrhythmia, SCD.

INTRODUCTION

The electrocardiogram (ECG) is the most commonly used test in cardiology. In this era of high technology and evidence-based medicine of the 21st century, the fundamentals of ECG applications in the diagnosis of arrhythmogenic right ventricular dysplasia (ARVD) still remain unshakable.

Since the beginning recognition of ARVD, [1-4] it is now appreciated as a genetic arrhythmogenic cardiomyopathy associated with an increased risk of sudden cardiac death (SCD). The pathology is characterized by the gradual loss of myocardium with fatty or fibrofatty tissue replacement, predominantly affecting the right ventricle and resulting in regional and global myocardial dysfunction. Areas of slow conduction and disparate refractoriness set the stage for reentrant ventricular tachyarrhythmias. ARVD development is mostly a concealed process in its early stages. Thus, SCD can be the first symptom occurring in young, apparently healthy individuals and endurance athletes. High risk individuals often experience the so-called ‘hot phase’ of the disease [5] featuring recurrent malignant ventricular tachyarrhythmias, whereas low risk individuals may have an uneventful clinical course. Because of the disease progression, congestive biventricular failure is the main cause of death and heart transplant may be required at the end stage of the disease [6, 7].

GENETIC BASIS AND THE PATHOGENESIS OF ARVD

Like many other familial disorders, there is a high degree of genetic heterogeneity in ARVD. To date, mutations of over 12 genes have been identified that can cause ARVD, or result in an ARVD phenotype, although some of these genes are also responsible for other diseases. Genes can be subgrouped into desmosomal and non-desmosomal types. Desmosomal genes are JUP encoding plakoglobin, [8-11] DSP for desmoplakin [12], PKP2, plakophilin-2 [13-15], PKP4, plakophilin-4 [16], DSG, desmoglein-2 [17, 18], and DSC2 for desmocollin-2 [19, 20]. Non-desmosomal genes are: TMEM43 [21] containing a response element for peroxisome proliferator-activated receptor gamma (PPAR-gamma), which is an adipogenic transcription factor regulating adipogenic pathway; CTNNA3, a gene encoding adherens junctional protein alpha-T-catenin [22] that binds plakophilins; and a list of genes that can result in “overlap syndromes” such as DES encoding desmin, a major intermediate filament protein interacting with the desmosome. DES mutations can cause skeletal myopathies, conduction disorders and an ARVD phenotype [23, 24]. TTN, a gene encoding titin expressed in both cardiac and skeletal muscle, is the largest protein in mammals. TTN mutations can cause hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), tibial muscular dystrophy and an ARVD phenotype [25]. PLN, encoding phospholamban, a Ca2+-ATPase regulator involved in assembly and disassembly of the desmosome. PLN mutations are associated with both DCM and ARVD [26]. LMNA, encoding Lamin A/C the nuclear matrix proteins and mutations of this gene can cause a variable of phenotypes so called ‘laminopathies’ characterized by alterations in adipose localization and replacement of skeletal myocytes by fibrofatty tissue. With over 100 mutations identified in DCM, LMNA is also responsible for ARVD [27]. RYR2, the cardiac ryanodine receptor gene mainly accounting for catecholaminergic polymorphic ventricular tachycardia, is linked to ARVD as well [28, 29].

Radical mutations have a high probability of being disease-causing in ARVD [30]. Compound or double heterozygous desmosomal mutations are not rare, and the extent of the disease is high compared to that in single-mutation carriers [13, 30-32]. Among genotyped...
individuals, a *PKP2* mutation is the most common according to multicenter/multinational registry studies [33-39]. In ARVD, the proband often exhibits a severe phenotype whereas reduced penetrance is prevalent among gene carriers [33-39].

The exact mechanism of the causative relationship between mutations in genes encoding both desmosomal and non-desmosomal proteins and the gradual loss of ventricular cardiomyocytes and fatty/fibrofatty replacement predominant in the right ventricle has not been elucidated [40-44]. The reduced desmosomal protein expression shown in endocardial biopsy samples [45] and fat droplet formation within the cardiomyocytes of the diseased hearts observed from histological studies [46, 47] have been replicated recently in *PKP2* mutant induced pluripotent stem cells (iPSCs)-derived cardiomyocytes [48]. The findings from patient specific iPSC-derived cardiomyocytes indicate that the PPAR-gamma pathway and cell metabolic derangement may account for apoptosis and lipogenesis [48]. Moreover, the *PKP2* knockout epicardial progenitor cells have shown adipocyte enlargement and migration, a plausible explanation for fat infiltration predominantly occurred in the right ventricle [43]. The vast majority of genotyped ARVD patients present with autosomal dominant inheritance, although an autosomal recessive pattern has also reported [8-14, 17, 18, 21, 49-51].

Establishing a clinical diagnosis of ARVD is based on a combination of characteristic abnormalities using an updated taskforce scoring system [52] that includes family history, ECG, cardiac imaging, endomyocardial biopsy and the identification of an ARVD-causing gene that can confirm the diagnosis. Since up to 50% of ARVD patients have no mutations in known genes, clinical assessment is essential for a correct diagnosis. A timely diagnosis can facilitate tailored treatment for arrhythmia control [53-55] and for prevention of SCD in high risk individuals using an implantable cardioverter-defibrillators (ICD) [56-60].

Among diagnostic modalities, the ECG is the first test. The vast majority of patients who meet ARVD Task force criteria present with ECG abnormalities, and many studies stress that ECG abnormalities are important elements in ARVD assessment and for family screening. The purpose of this article, therefore, is to describe the common ECG abnormalities associated with ARVD that have been observed by the authors over the years, and by literature review. Recognizing the characteristic ECG changes can increase diagnostic accuracy, and help identify affected members at an early and hopefully pre-symptomatic stage, in a timely and cost effective manner.

I. ECG IN SINUS RHYTHM

As with any ECG interpretations, the sequence of ECG assessment in ARVD should start from heart rate, rhythm, P-QRS-ST-T morphology, amplitude, duration and axis. Visual inspection may take a few minutes. It is important to observe ECG patterns in all 12 leads. Patient’s age, gender, medication and/or device therapy should be taken into consideration during ECG assessment.

1. Heart Rate

Based on our observations, the average heart rate in ARVD adults (n= 120, age 39±13 yrs) is within the lower normal range (63±13 bpm). Sinus bradycardia seems more common (37% vs. 20%, p=ns), though the difference did not reach statistical significance when compared with age and gender matched controls. There are case reports of ARVD patients presenting with sick sinus syndrome [61, 62]. Those observations may have been influenced by several factors: 1) sino-atrial involvement during disease progression; 2) some of the ARVD patients were athletes; and 3) use of sotalol, a drug with both beta-blocker and Class III antiarrhythmic effects, commonly prescribed to patients with frequent ventricular tachyarrhythmias [53]. The lower heart rate in ARVD may be of use in differentiating it from acute myocarditis, pericarditis and pulmonary embolism (PE). Although right precordial T wave inversion can be seen in those conditions, they are more likely associated with inappropriate sinus tachycardia. Moreover, the presence of S1Q3T3R, defined as a deep or broad S wave in lead I, Q wave and T wave inversion in lead III, is a signature change of acute PE [63-65].

2. P Wave

P wave abnormalities are common in ARVD [66]. Notched, widened (P wave duration >110 ms), flat or small peaked P wave are seen in up to 50% of ARVD patients in our study cohort consisting of 120 adults and 20 children. Nevertheless, P wave morphology variations are also found in 37% of age and gender comparable control subjects. Thus presence of P wave abnormalities in ARVD patients may reflect atrial involvement, but they may not necessarily add power to an ARVD diagnosis.

3. P-R Interval

A-V conduction delay is common in ARVD [67, 68]. Based on our observations the P-R interval is significantly prolonged in ARVD compared to control subjects (170±32 ms vs 154±21 ms, p <0.0001). First degree A-V block (AVB) (PR interval >200 msec) is seen in 16% of ARVD patients. In our ARVD cohort first degree AVB is seen in 15% of ARVD children, indicating that the conduction system may be involved at the early stage of the disease process. Second and third degree AVB are also reported in ARVD patients [67].

We do need to keep in mind that AVB is also common in patients with right ventricular cardiac sarcoidosis (CS) [69, 70]. The latter is a multisystem granulomatous disorder of unknown etiology. CS can mimic ARVD by ECG presentations, EP study results and even with desmosomal gene expression [71]. Unfortunately, applying the taskforce criteria cannot reliably separate CS from ARVD [72, 75].

4. QRS Complex

The regional conduction delay and the loss of myocardium due to ARVD are well reflected in the QRS complex, including changes in duration, morphology and amplitude.
4.1. Regional Prolongation of QRS Duration

Since the first description of right ventricular parietal block [76], localized QRS prolongation in the right precordial leads, such as QRS duration (QRSD) >110 ms, and the terminal S wave prolongation (≥ 55 ms) in V1-3 have been much appreciated as non-invasive indicators of activation delay occurred in the diseased region of the right ventricle [77-82]. Those ECG markers have been factored in the taskforce criteria for ARVD diagnosis [52, 83].

4.2. QRS Fragmentation

A fragmented QRS (fQRS) refers to the ‘slurs or notches’ appeared on the R or S wave or if the total QRS complex had ≥ 4 spikes. fQRS can be a normal variant if it appeared randomly in just a few leads. fQRS presenting in multiple leads is more likely pathologic. The underlying cause is the regional delay in propagation of ventricular depolarization [84]. fQRS is highly prevalent in ARVD patients when applied to amplified and modified ECG recording techniques, including the use of the Fontaine Leads System [85-87]. In real world practice, nevertheless, most ECGs available from ARVD patients and family members were obtained by using standard ECG recording technique. Based on our observations, fQRS is easily recognizable from standard ECGs and they are much more common in ARVD patients (n=140) when compared with 100 control subjects (61% vs 37%, p < 0.001). Among them a notch before the end of R or S wave (Fig. 1) is characteristic, seen in 51% of ARVD vs 26% in controls, p <0.001. In ARVD, fQRS is often seen in multiple leads. Such changes, however, are common in CS as well. In the latter, the QRS complex is wider [72]. Since fQRS is also prevalent in other types of cardiomyopathies (both ischemic and non-ischemic) [88, 89], Brugada syndrome [84] and in normal subjects, its use in ARVD diagnosis is limited.

4.3. Reduced QRS Amplitude

We have found that reduced QRS amplitude in ≥ 6 leads is seen in 66% of 140 ARVD patients in our study cohort. This feature may be of help in differentiating ARVD from athlete heart. The loss of heart muscle is a major feature in ARVD, and the likely cause of reduced QRS amplitude seen in ARVD patients, especially those in the advanced or late stage of the disease [78, 80]. Since reduced QRS amplitude can be a normal variant or found in many other diseases, its lone use in ARVD diagnosis is limited.

4.4. Poor R Wave Progression (PRWP)

The most prevalent ECG manifestation in ARVD, caused by p.S358L mutation in TMEM43 gene, is PRWP. Affected males are twice as likely to develop PRWP as affected females [90]. PRWP is also common in other ARVD patients with severe RV dilatation [80]. The most likely cause of PRWP is clockwise rotation caused by RV enlargement.

4.5. QRS Axis

Unlike other types of RV enlargement, left axis deviation is common in ARVD, seen in 22% in our study cohort. Left axis deviation, when associated with left anterior fascicular block, is more common in patients with LV involvement or in the later stages of ARVD [80].

4.6. Right Bundle Branch Block (RBBB)

Complete or incomplete RBBB is common in ARVD [76, 79, 91], indicating that the right heart Purkinje network of the conduction system is impaired. In advanced or later stages, CRBBB is associated with a poor prognosis [92]. CRBBB in ARVD has the following features (Fig. 2): 1) a lower magnitude of both R wave and QRS complex in V1-2; 2) a smaller ratio of R'/S in V1-2; and 3) T wave inversion in V1-3 or beyond is much more common (67% vs. 33%, p

Fig. (1). An ECG from a 46-y-old male Caucasian ARVD patient showing 1) sinus bradycardia; 2) interpolated PVCs in LBBB morphology; 3) IRBBB; 4) though there are some artifacts, the terminal S wave prolongation (≥55 ms) with a slur, and an epsilon wave that is best appreciated in Lead V1; 4) T wave inversion in V1-4.
<0.0001). The rather different looking RBBB morphology seen in ARVD, based on the findings from epicardial mapping and histological data, is likely attributable not only to the impaired bundle branch but also to distal block in the right ventricular wall due to the irregular and delayed propagation of activation in the zones of dysplasia [76]. Therefore, we call it a more than complete (or incomplete) RBBB.

5. Epsilon Wave

First reported in 1977 [1], the Epsilon wave is a reflection of ‘mega’ late potentials on the surface ECG that can be seen in patients with advanced or late stage of ARVD [68, 79, 80, 93, 94]. In the diseased region of the right ventricle, the islands of the surviving cardiomyocytes bordered by or embedded in interstitial fibrosis and/or fat causes delayed activation in those areas which results in delayed (late) potentials. Depending on the severity of myocardial damage, the delayed and distort activation may occur before the end of the QRS complex or after the ST segment [1]. Nevertheless, the Epsilon wave is best appreciated in the beginning of the ST segment as small wiggles or a tiny protrusion [1, 87]. Moreover, Epsilon waves are most prominent in the right precordial leads though they can be seen in the limb leads or in all 12 leads (Figs. 2-3). Since the magnitude of the Epsilon wave is generally small, applying Fontaine leads system [87], a very simple method, can amplify Epsilon waves and thereby increase the detection sensitivity significantly [86, 95]. Presence of Epsilon wave is considered as a major diagnostic criterion in ARVD [52, 83] but it is also found in other diseases if late potentials are manifest on the surface ECG [96-101]. For example, Epsilon waves in CS are much more coarse due to extensive formation of fibrosis in the RV [98].

6. ST Segment

ST elevation is not uncommon in ARVD [102]. In our study cohort, 37% of ARVD patients had a ST elevation. Among these, 42% showed a small notch (Fig. 1) in the first half of the ST segment and such findings are more frequently seen in patients in the presence of Epsilon waves.

7. T Wave Inversion in the Right Precordial Leads

Based on a number of multicenter/multinational studies [3, 78-80, 103, 104], T wave inversion in V1-3 is one of the most common ECG abnormalities in ARVD. Therefore it has been upgraded to a major taskforce diagnostic criterion [52]. In ARVD the regional conduction delay and RV dilatation [80, 105] may be the causes of T wave inversion in V1-3 or beyond. In other words, it is a secondary rather than a primary repolarization abnormality. T wave inversion beyond V3 is more common in ARVD patients in the advanced stage of the disease with severe RV dilatation and LV involvement [80, 106]. Thus it has been considered a risk factor[102] and perhaps an indication of a poor prognosis. T wave inversion in the right precordial leads can also be seen in many other conditions such as acute PE, athlete heart [107-109], Brugada syndrome, long QT syndrome caused by
II. ARVD-RELATED ARRHYTHMIA

1. Atrial Arrhythmia

Atrial extrasystoles, flutter and atrial fibrillation are not uncommon in ARVD [110] especially in those with moderate/severe tricuspid regurgitation and markedly enlarged right ventricles [5, 111, 112]. They can occur prior to or during manifest ventricular arrhythmia [111]. Atrial involvement is a likely cause of these arrhythmias [61, 62].

2. Ventricular Arrhythmia

The increased susceptibility to ventricular tachyarrhythmia and SCD is a main feature of ARVD that led to its first recognition in 1977 [1]. Symptoms such as palpitations, dizziness, presyncope and syncope are caused by frequent premature contractions (PVCs), sustained, or non-sustained VT. Since ectopic beats from the ‘triangle of dysplasia’ [3] right ventricular origin is most common, these VTs have a left bundle branch block (LBBB) morphology with superior, inferior or indeterminate axis [52]. VT and PVCs (>500 per 24 hours) in LBBB morphology are considered a minor diagnostic criteria [52]. In many cases VT comes in 'hot phases' thus viral infection has been suspected as a prerequisite [113] or a superimposed factor onto ARVD. Drug therapy is empiric. Sotalol or amiodarone in combination with beta-blockers is preferred but their effectiveness is limited due to the nature of the disease [53, 60]. The slow conduction in the diseased region first recorded during epicardial mapping confirmed re-entry as the mechanism of resistant ventricular tachycardia (VT). This led the pioneer investigators to use aggressive therapeutic approaches such as ventriculotomy [1] and multi-session fulgurations with high energy DC ablation [114, 119]. In recent years, the combined endocardial and epicardial VT ablation incorporating scar de-channeling seems promising in achieving short- and mid-term success [54].

Since ARVD is often a silent cardiomyopathy among affected young people or endurance athletes, and VT degenerating into ventricular fibrillation (VF) is the cause of SCD, ICD therapy is highly effective in cases of aborted SCD and unstable VT, and is recommended to high risk individuals for primary and secondary SCD prevention purposes [56-60].

The differential diagnosis for individuals with recurrent VT with a LBBB morphology is idiopathic right ventricular outflow tract VT (RVOT). The prognosis for these patients is usually benign. Unlike ARVD triggered automatic activity accounts for the vast majority of RVOT VTs [120]. A number of studies have reported the differences in VT morphology between ARVD and RVOT with regard to the duration, fragmentation, frontal axis and the origin of QRS complex [121, 122]. Nevertheless, there is a considerable overlap in VT morphology between these two entities. Sometimes at fast rates, separating the oscillating-like R wave from S wave or the wide QRS complex from T wave is nearly impossible, especially in emergency situations. A careful ECG evaluation in VT and in sinus rhythm is necessary [52, 123, 124].

III. LATE POTENTIALS

Late potentials refer to the low-amplitude, high-frequency, and altered frequency components in the terminal
QRS complex. They are too small to be visible on the surface ECG tracing. This limitation however was solved by high resolution signal-averaged ECG (SAECG), a summation averaging technique first proposed in 1977 [1] and refined thoroughly over time [125, 126]. The underlying mechanism is all the same regarding late potentials, Epsilon waves, delayed or fragmented electrograms recorded during endomyocardial mapping and the presence of low-voltage areas detected by electroanatomic voltage mapping in the right ventricle of ARVD patients. Presence of late potentials is a minor task force criterion [52]. Utilizing SAECG has shown an improved diagnostic accuracy [127]. In ARVD the prevalence of late potentials is much higher (69%) than that of Epsilon waves in individuals met the taskforce criteria [127]. The prevalence is also higher in ARVD family members (16%), therefore, it can be used for family screenings [128]. In contrast, late potential is mostly negative in RVOT individuals with no apparent structural heart abnormalities [129].

CONCLUSION

In summary, ARVD is a genetic arrhythmogenic cardiomyopathy associated with an increased risk of SCD. Mutations in both desmosomal and non-desmosomal genes can lead to a gradual loss of myocardium and fatty or fibrofatty replacement predominantly affecting the right ventricle. ARVD development is a concealed process at the early stage. Upon diagnosis, most patients present with ECG abnormalities, indicating the ECG changes may have occurred long before the development of malignant arrhythmias. ECG abnormalities are characteristic in the majority of patients who meet the task force criteria. Recognizing the common manifestations of ARVD on ECG may help improve diagnostic accuracy. Moreover it can be useful in identifying affected family members. ECG, nevertheless, cannot replace or substitute other diagnostic modalities towards ARVD diagnosis.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

ACKNOWLEDGEMENTS

1. Grants: AHA SDG0735474N, SSRF 2011-2012 and W.W. Smith Charitable Trust.
2. Organizations and individuals: North American ARVD Registry, Johns Hopkins ARVD Registry, Chinese ARVD Registry, Mrs. Micheline (Tink) Long and the International ARVD Family Support Network, as well as colleagues from France, Italy and all over the world who contributed to the ARVD investigations since 1977.

REFERENCES

[1] Fontaine G, Guiraudon G, Frank R. Stimulation studies and epicardial mapping in ventricular tachycardia: A study of mechanisms and selection for surgery HE Kulbertus (Ed.), Reentrant Arrhythmias, Lancaster, England. 1977 pp. 334-50.
[2] Fontaine G, Guiraudon G, Frank R, et al. Arrhythmogenic right ventricular dysplasia and uhf's disease. Arch Mal Coeur Vaiss 1982; 75: 361-71.
[3] Marcus F, Fontaine GH, Guiraudon G, et al. Right ventricular dysplasia: A report of 24 adult cases. Circulation 1982; 65: 384-98.
[4] Dungan WT, Garson A Jr., Gillette PC. Arrhythmogenic right ventricular dysplasia: A cause of ventricular tachycardia in children with apparently normal hearts. Am Heart J 1981; 102: 745-50.
[5] Peters S. Long-term follow-up and risk assessment of arrhythmogenic right ventricular dysplasia/cardiomyopathy: Personal experience from different primary and tertiary centres. J Cardiovasc Med (Hagerstown) 2007; 8: 521-6.
[6] Nemec J, Edwards BS, Osborn MJ, Edwards WD. Arrhythmogenic right ventricular dysplasia masquerading as isolated cardiomyopathy. Am J Cardiol 1999; 84: 237-9.
[7] Hulot JS, Jouve X, Empana JP, Frank R, Fontaine G. Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation 2004; 110: 1879-84.
[8] McKoy G, Protonotarios N, Crosby A, et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (naxos disease). Lancet 2000; 355: 2119-24.
[9] Protonotarios N, Tsatsopoulu A, Anastasakis A, et al. Genotype-phenotype assessment in autosomal recessive arrhythmogenic right ventricular cardiomyopathy (naxos disease) caused by a deletion in plakoglobin. J Am Coll Cardiol 2001; 38: 1477-84.
[10] Asimaki A, Syriss P, Wichter T, Matthias P, Saffitz JE, McKenna WJ. A novel dominant mutation in plakoglobin causes arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 2007; 81: 964-73.
[11] Coonar AS, Protonotarios N, Tsatsopoulu A, et al. Gene for arrhythmogenic right ventricular cardiomyopathy with diffuse nonepidermolytic palmoplantar keratoderma and woolly hair (naxos disease) maps to 17q21. Circulation 1998; 97: 2049-58.
[12] Rampazzo A, Nava A, Malacrida S, et al. Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 2002; 71: 1200-6.
[13] Gerull B, Heuser A, Wichter T, et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet 2004; 36: 1162-4.
[14] Dalal D, Molin LH, Piccini J, et al. Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation 2006; 113: 1641-9.
[15] van der Zwaag PA, Cox MG, van der Werf C, et al. Recurrent and founder mutations in the netherlands : Plakophilin-2 p.Arg79x mutation causing arrhythmogenic right ventricular cardiomyopathy/dysplasia. Neth Heart J 2010; 18: 583-91.
[16] Xu T, Yang Z, Yatta M, et al. Multidisciplinary Study of Right Ventricular Dysplasia I. Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2010; 55: 587-97.
[17] Pilichou K, Nava A, Basso C, et al. Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. Circulation 2006; 113: 1641-9.
[18] Awad MM, Dalal D, Cho E, et al. Dsg2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathy. Am J Hum Genet 2006; 79: 136-42.
[19] Heuser A, Plovie ER, Ellinor PT, et al. Mutant desmocollin-2 causes arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 2006; 79: 1081-8.
[20] Benfagna G, De Bortoli M, Nava A, et al. Missense mutations in desmocollin-2 n-terminus, associated with arrhythmogenic right ventricular cardiomyopathy, affect intracellular localization of desmocollin-2 in vitro. BMC Med Genet 2007; 8: 65.
[21] Merner ND, Hodgkinson KA, Haywood AF, et al. Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the tmem43 gene. Am J Hum Genet 2008; 82: 809-21.
[22] van Hengel J, Calore M, Bauge B, et al. Mutations in the area composita protein alphat-catenin are associated with arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2013; 34: 201-10.
[23] van Spauendonck-Zwarts KY, van der Kooi AJ, van den Berg MP, et al. Recurrent and founder mutations in the netherlands: The
cardiac phenotype of des founder mutations p.S13F and p.N342D. Neth Heart J 2012; 20: 219-28.

[24] van Tintelen JP, Van Gelder IC, Asimaki A, et al. Severe cardiac phenotype with right ventricular predominance in a large cohort of patients with a single missense mutation in the des gene. Heart Rhythm 2009; 6: 1574-83.

[25] Taylor M, Graw S, Sinagra G, et al. Genetic variation in titin in arrhythmogenic right ventricular cardiomyopathy-overlap syndromes. Circulation 2011; 124: 876-85.

[26] van der Zwaag PA, van Rijssingan IA, Asimaki A, Jongbloed JD, van Veldhuisen DJ, Wiestfeld AC, Cox MG, van Lochem LT, de Boer RA, et al. Phospholamban r4del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: Evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail 2012; 14: 1199-207.

[27] Quarta G, Syrris P, Ashworth M, et al. Mutations in the lamin a/c gene mimic arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2012; 33: 1128-36.

[28] Tiso N, Stephan DA, Nava A, et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (arvd2). Hum Mol Genet 2001; 10: 189-94.

[29] Pamuru PR, Maithili DV, Mohiuddin K, Calambur N, Nallari P. Novel mutations in arrhythmogenic right ventricular cardiomyopathy from indian population. Indian J Hum Genet 2011; 17: 70-6.

[30] Kaplinger JD, Landstrom AP, Salisbury BA, et al. Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise. J Am Coll Cardiol 2011; 57: 2317-27.

[31] Christensen AH, Benn M, Bundgaard H, Tybjerg-Hansen A, Haunso S, Svendsen JH. Wide spectrum of desmosomal mutations in danish patients with arrhythmogenic right ventricular cardiomyopathy. J Med Genet 2010; 47: 736-44.

[32] Bause B, Nava A, Beffagna G, et al. Multiple mutations in desmosomal proteins encoding genes in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm 2010; 7: 22-9.

[33] Dalal D, James C, Devanagondi R, et al. Penetration of mutations in plakophilin-2 among families with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 2006; 48: 1416-24.

[34] van der Smart JI, van der Zwaag PA, van Tintelen JP, et al. Clinical and genetic characterization of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy caused by a plakophilin-2 splice mutation. Cardiology 2012; 123: 181-9.

[35] van Tintelen JP, Entius MM, Bhuiyan ZA, et al. Plakophilin-2 mutations are the major determinant of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation 2006; 113: 1650-8.

[36] den Haan AD, Tan BY, Zikusoka MN, et al. Comprehensive desmosome mutation analysis in north americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Cardiovasc Genet 2009; 2: 428-35.

[37] Qiu X, Liu W, Hu D, et al. Mutations of plakophilin-2 in chinese with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Am J Cardiol 2009; 103: 1439-44.

[38] Fressart V, Duthoit G, Donal E, et al. Desmosomal gene analysis in arrhythmogenic right ventricular dysplasia/cardiomyopathy: Spectrum of mutations and clinical impact in practice. Europace 2010; 12: 861-8.

[39] Ohno S, Nagaoka I, Fukuyama M, et al. Age-dependent clinical and genetic characteristics in japanese patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circ J 2013; 77(6): 1534-42.

[40] Garcia-Gras E, Lombardi R, Giocondo MJ, et al. Suppression of canonical wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. J Clin Invest 2006; 116: 2012-21.

[41] Delmar M. Desmosome-ion channel interactions and their possible role in arrhythmogenic cardiomyopathy. Pediatr Cardiol 2012; 33: 975-9.

[42] Joshi-Mukherjee R, Coombs W, Musa H, Oxford E, Taffet S, Delmar M. Characterization of the molecular phenotype of two arrhythmogenic right ventricular cardiomyopathy (arvc) related plakophilin-2 (ppk2) mutations. Heart Rhythm 2008; 5: 1715-23.

[43] Matthes SA, Taffet S, Delmar M. Plakophilin-2 and the migration, differentiation and transformation of cells derived from the epicardium of neonatal rat hearts. Cell Commun Adhes 2011; 18: 73-84.

[44] Oxford EM, Everitt M, Coombs W, et al. Molecular composition of the intercalated disc in a spontaneous canine animal model of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heat Rhythm 2007; 4: 1196-205.

[45] Asimaki A, Tandri H, Huang H, et al. A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N Engl J Med 2009; 360: 1075-84.

[46] d’Amati G, de Gioia CR, Giordano C, Gallo P, Myocyte transdifferentiation: A possible pathogenetic mechanism for arrhythmogenic right ventricular cardiomyopathy. Arch Pathol Lab Med 2000; 124: 287-90.

[47] d’Amati G, Leone O, di Gioia CR, et al. Arrhythmogenic right ventricular cardiomyopathy: Clinicopathologic correlation based on a revised definition of pathologic patterns. Hum Pathol 2001; 32: 1078-86.

[48] Kim C, Wong J, Wen J, et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific ipscs. Nature 2013; 494: 105-10.

[49] Simpson MA, Mansour S, Ahnood D, et al. Homozygous mutation of desmocollin-2 in arrhythmogenic right ventricular cardiomyopathy with mild palmoplantar keratoderma and woolly hair. Cardiology 2009; 113: 28-34.

[50] Awad MM, Dalal D, Tichnell C, et al. Recessive arrhythmogenic right ventricular dysplasia due to novel cryptic splice mutation in pkp2. Hum Mutat 2006; 27: 1157.

[51] Alcalai R, Metzger S, Rosenheck S, Meiner V, Chajek-Shaul T. A recessive mutation in desmoplakin causes arrhythmogenic right ventricular dysplasia, skin disorder, and woolly hair. J Am Coll Cardiol 2003; 42: 319-27.

[52] Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: Proposed modification of the task force criteria. Eur Heart J 2010; 31: 806-14.

[53] Marcus GM, Glnidden DV, Polonsky B, et al. Multidisciplinary Study of Right Ventricular Dysplasia I. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: A report from the north american arvc registry. J Am Coll Cardiol 2009; 54: 609-15.

[54] Berruezo A, Fernandez-Armenta J, Mont L, et al. Combined endocardial and epicardial catheter ablation in arrhythmogenic right ventricular dysplasia incorporating scar dechanneling technique. Circ Arrhythm Electrophysiol 2012; 5: 111-21.

[55] Pokushalov E, Romanov A, Turov A, Atyomenko S, Shirokova N, Karaskov A. Percutaneous epicardial ablation of ventricular tachycardia after failure of endocardial approach in the pediatric population with arrhythmogenic right ventricular dysplasia. Heart Rhythm 2010; 7: 1406-10.

[56] Corrado D, Leonis L, Link MS, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2003; 108: 3084-91.

[57] Bhonsale A, James CA, Tichnell C, et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol 2011; 58: 1485-96.

[58] Dalal D, Nasir K, Bommia C, et al. Arrhythmogenic right ventricular dysplasia: A united states experience. Circulation 2005; 112: 3823-32.

[59] Li CH, Lin YJ, Huang JL, et al. Long-term follow-up in patients with arrhythmogenic right ventricular cardiomyopathy. J Cardiovasc Electrophysiol 2012; 23: 750-6.

[60] Wichter T, Paul TM, Eckardt L, et al. Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation and defibrillator therapy. Herz 2005; 30: 91-101.

[61] Takemura N, Kono K, Tadokoro K, et al. Right atrial abnormalities in a patient with arrhythmogenic right ventricular cardiomyopathy without ventricular tachycardia. J Cardiovasc 2008; 51: 205-9.

[62] Balderramo DC, Caeiro AA. Arrhythmogenic right ventricular dysplasia and sick sinus syndrome. Medicina (B Aires) 2004; 64: 439-441.
with arrhythmogenic right ventricular dysplasia cardiomyopathy provides novel insights into patterns of disease expression. Circulation 2007; 115: 1710-20.

[107] Wilson MG, Sharma S, Carre F, et al. Significance of deep t-wave inversions in asymptomatic athletes with normal cardiovascular examinations: Practical solutions for managing the diagnostic conundrum. Br J Sports Med 2012; 46 Suppl 1: i51-8.

[108] Magalski A, Maron BJ, Main ML, et al. Relation of race to electrocardiographic patterns in elite american football players. J Am Coll Cardiol 2008; 51: 2250-5.

[109] Magalski A, McCoy M, Zabel M, et al. Cardiovascular screening with electrocardiography and echocardiography in collegiate athletes. Am J Med 2011; 124: 511-8.

[110] Tonet JL, Castro-Miranda R, Iwa T, Pouliain F, Frank R, Fontaine GH. Frequency of supraventricular tachyarrhythmias in arrhythmogenic right ventricular dysplasia. Am J Cardiol 1991; 67: 1153.

[111] Chu AF, Zado E, Marchinski FE. Atrial arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and ventricular tachycardia. Am J Cardiol 2010; 106: 720-2.

[112] Jinnouchi J, Nakane H, Kitayama J, Fukahori M, Ibayashi S, Iida M. A case of cardioembolic brain infarction in arrhythmogenic right ventricular dysplasia. Rinsho Shinkeigaku 2005; 45: 744-7.

[113] Sabel KG, Blomstrom-Lundqvist C, Olsson SB, Enestrom S. Arrhythmogenic right ventricular dysplasia in brother and sister: Is it related to myocarditis? Pediatr Cardiol 1990; 11: 113-6.

[114] Fontaine G, Cansell A, Tonet JL, et al. Techniques and methods for catheter endocardial fulguration. Pacing Clin Electrophysiol 1988; 11: 592-602.

[115] Fontaine G, Frank R, Gallais Y, et al. Radiofrequency catheter ablation of ventricular tachycardia. Arch Mal Coeur Vaiss 1996; 89 Spec No 1: 99-107.

[116] Fontaine G, Frank R, Gallais Y, et al. Fulguration and radiofrequency in ventricular tachycardia. Arch Mal Coeur Vaiss 1994; 87: 1589-607.

[117] Fontaine G, Tonet J, Gallais Y, et al. Ventricular tachycardia catheter ablation in arrhythmogenic right ventricular dysplasia: A 16-year experience. Curr Cardiol Rep 2000; 2: 498-506.

[118] Frank R, Tonet J, Rougier I, Gallais Y, Fontaine G, Grosogoeat Y. Endocardial fulguration for the treatment of ventricular tachycardia. Experience with 69 cases. Arch Inst Cardiol Mex 1990; 60: 491-7.

[119] Leclercq JF, Counel P. Characteristics, prognosis and treatment of the ventricular arrhythmias of right ventricular dysplasia. Eur Heart J 1989; 10 Suppl D: 61-7.

[120] O’Donnell D, Cox D, Bourke J, Mitchell L, Furniss S. Clinical and electrophysiological differences between patients with arrhythmogenic right ventricular dysplasia and right ventricular outflow tract tachycardia. Eur Heart J 2003; 24: 801-10.

[121] Ainsworth CD, Skanes AC, Klein GJ, Gula LJ, Yee R, Krahn AD. Differentiating arrhythmogenic right ventricular cardiomyopathy from right ventricular outflow tract ventricular tachycardia using multilead qrs duration and axis. Heart Rhythm 2006; 3: 416-23.

[122] Hoffmayer KS, Machado ON, Marcus GM, et al. Electrocardiographic comparison of ventricular arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy and right ventricular outflow tract tachycardia. J Am Coll Cardiol 2011; 58: 831-8.

[123] Morin DP, Mauer AC, Gear K, et al. Usefulness of precordial t-wave inversion to distinguish arrhythmogenic right ventricular cardiomyopathy from idiopathic ventricular tachycardia arising from the right ventricular outflow tract. Am J Cardiol 2010; 105: 1821-4.

[124] Hoffmayer KS, Bhave PD, Marcus GM, et al. An electrocardiographic scoring system for distinguishing right ventricular outflow tract arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy from idiopathic ventricular tachycardia. Heart Rhythm 2013; 10: 477-82.

[125] Kinoshita O, Fontaine G, Rosas F, et al. Optimal high-pass filter settings of the signal-averaged electrocardiogram in patients with arrhythmogenic right ventricular dysplasia. Am J Cardiol 1994; 74: 1074-5.

[126] Kinoshita O, Fontaine G, Rosas F, et al. Time- and frequency-domain analyses of the signal-averaged ecg in patients with arrhythmogenic right ventricular dysplasia. Circulation 1995; 91: 715-21.

[127] Kamath GS, Zareba W, Delaney J, et al. Value of the signal-averaged electrocardiogram in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm 2011; 8: 256-62.

[128] Hermida JS, Minassian A, Jarry G, et al. Familial incidence of late ventricular potentials and electrocardiographic abnormalities in arrhythmogenic right ventricular dysplasia. Am J Cardiol 1997; 79: 1375-80.

[129] Grimm W, List-Hellwig E, Hoffmann J, et al. Magnetic resonance imaging and signal-averaged electrocardiography in patients with repetitive monomorphic ventricular tachycardia and otherwise normal electrocardiogram. Pacing Clin Electrophysiol 1997; 20: 1826-33.